XML 100 R80.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent events (Details) - Subsequent events
$ in Millions
Nov. 19, 2021
USD ($)
Nov. 01, 2021
USD ($)
item
Asset License and Contract Assignment Agreement with Revelar    
Subsequent Event [Line Items]    
Success-based milestone payments based on achievement   $ 100.0
Maximum number of additional antibody therapeutics under license | item   5
License period   4 years
Maximum committed investment   $ 10.0
Percentage of undiluted ownership excluding shares and options   49.80%
SAFE investment in exchange for cash investment   $ 5.0
AbX Biologics, Inc.    
Subsequent Event [Line Items]    
Purchase consideration $ 140.0  
Cash consideration 10.0  
Contingent payment $ 40.0